Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma

We previously reported that BV enabled successful reduced-intensity allogeneic hematopoietic cell transplantation (RIC-alloHCT) in patients with relapsed Hodgkin lymphoma, after a median follow-up of 14.4 months. We now provide an updated report on 21 patients who were treated from 2009–2012 with BV...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Chen, Robert, Palmer, Joycelynne M., Tsai, Ni-Chun, Thomas, Sandra H., Siddiqi, Tanya, Popplewell, Leslie, Farol, Len, Nademanee, Auayporn, Forman, Stephen J.
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4194250/
https://ncbi.nlm.nih.gov/pubmed/25008328
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2014.06.037
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars